Fusion Pharmaceuticals enters license agreement with Heidelberg Univ., Euratom

Fusion Pharmaceuticals announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre. The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T for the treatment of prostate specific membrane antigen expressing cancers. In addition, Fusion and the Licensors have signed an agreement to settle the parties’ dispute related to an inter partes review of a U.S. patent owned by the Licensors which was instituted in August 2023 by the United States Patent and Trademark Board. As announced in January 2024, Fusion and the U.S. Food and Drug Administration reached alignment on Fusion’s Phase 2/3 protocol for FPI-2265 in patients with mCRPC who have progressed following treatment with lutetium-based radiopharmaceuticals. The updated development plan includes a Phase 2 dose optimization lead-in, expected to complete enrollment by the end of 2024, and a Phase 3 registrational trial expected to begin in 2025. Under the terms of the license agreement, Fusion will pay the Licensors an aggregate upfront fee of EUR1.0M, in addition to certain regulatory milestones upon potential approval and low single-digit royalties on future net sales of applicable products.